Welcome and Methods
From www.HCVGuidance.org on June 08, 2020

Introduction

NOTICE: Guidance for hepatitis C treatment in adults is changing constantly with the advent of new therapies and other developments. A static version of this guidance, such as printouts of this website material, booklets, slides, and other materials, may be outdated by the time you read this. We urge you to review this guidance on this website (www.hcvguidelines.org) for the latest recommendations.

The landscape of treatment for hepatitis C virus (HCV) infection has evolved substantially since the introduction of highly effective HCV protease inhibitor therapies in 2011. The pace of change has increased rapidly as numerous new drugs with different mechanisms of action have become available over the past few years. To provide healthcare professionals with timely guidance as new therapies become available and are integrated into HCV regimens, the Infectious Diseases Society of America (IDSA) and American Association for the Study of Liver Diseases (AASLD), developed a web-based process for the rapid formulation and dissemination of evidence-based, expert-developed recommendations for hepatitis C management.

The AASLD/IDSA guidance on hepatitis C addresses management issues ranging from testing and linkage to care, the crucial first steps toward improving health outcomes for HCV-infected persons, to the optimal treatment regimen in particular patient situations. Recommendations are evidence based and rapidly updated as new data from peer-reviewed research become available. For each treatment option, recommendations reflect the best possible management for a given patient and a given point of disease progression. Recommendations are rated with regard to the level of the evidence and strength of the recommendation. The AASLD/IDSA guidance on hepatitis C is supported by the membership-based societies and not by pharmaceutical companies or other commercial interests. The governing boards of AASLD and IDSA have appointed an oversight committee of 4 co-chairs and selected panel members from the societies.

This guidance should be considered a living document in that the recommendations are updated frequently as new information and treatments become available. This continually evolving report provides guidance on FDA-approved regimens. At times, it may also recommend off-label use of certain drugs or tests, or provide guidance for regimens not yet approved by the FDA. Readers should consult prescribing information and other resources for further information. In the future, treatment recommendations may be further guided by data from cost-effectiveness studies.

Last update: November 6, 2019
Methods

The guidance was developed by a panel of HCV experts in the fields of hepatology and infectious diseases using an evidence-based review of information that is largely available to healthcare practitioners. The processes and detailed methods for developing the guidance are detailed in Methods Table 1. Recommendations are rated according to the strength of the recommendation and quality of the supporting evidence (see Methods Table 2) (AASLD-IDSA, 2015). Commonly used abbreviations are defined in Methods Table 3.

The panel regularly reviews available data to determine whether a regimen should be classified as recommended, alternative, or not recommended for particular patient subgroups. Recommended regimens are those that are favored for most patients in a given subgroup based on optimal efficacy, favorable tolerability and toxicity profiles, treatment duration, and pill burden. Alternative regimens are those that are effective but, relative to recommended regimens, have potential disadvantages, limitations for use in certain patient populations, or less supporting data than recommended regimens. In certain circumstances, an alternative regimen may be optimal for a specific patient situation. Not recommended regimens are clearly inferior to recommended or alternative regimens due to factors such as lower efficacy, unfavorable tolerability and toxicity, longer treatment duration, and/or higher pill burden. Unless otherwise indicated, such regimens should not be administered to patients with HCV infection.

Last update: November 6, 2019

Table 1. Summary of the Process and Methods for the Guidance Development

<table>
<thead>
<tr>
<th>Topic</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statement of need</td>
<td>Increased awareness of the rising number of complications of hepatitis C virus (HCV) infection, the recent screening initiatives by the Centers for Disease Control and Prevention (CDC) and US Preventive Services Task Force (USPSTF), and the rapid evolution of highly effective antiviral therapy for HCV infection have driven a need for timely guidance on how new developments change practice for healthcare professionals.</td>
</tr>
<tr>
<td>Goal of the guidance</td>
<td>The goal of the guidance is to provide up-to-date recommendations to healthcare practitioners on the optimal screening, management, and treatment for persons with HCV infection in the United States, considering the best available evidence. The guidance is updated regularly as new data, information, and tools and treatments become available.</td>
</tr>
<tr>
<td>Panel members</td>
<td>Panel members are chosen based on their expertise in the diagnosis, management, and treatment of HCV infection. Members from the fields of hepatology and infectious diseases are included, as well as HCV community representatives. Members are appointed by the sponsor societies after vetting by an appointed sponsor society committee. The panel chairs are appointed by the society boards, 2 each from the sponsor societies. All panel chairs and members serve as uncompensated volunteers for defined terms (2 to 3 years), which may be renewed based on panel needs.</td>
</tr>
<tr>
<td>Conflict of interest management</td>
<td>The panel was established with the goal of having no personal (ie, direct payment to the individual) financial conflicts of interest among its chairs and among fewer than half of its panel members. All potential panel members are asked to disclose any personal relationship(s) with pharmaceutical, biotechnology, medical device, or health-related companies or ventures that</td>
</tr>
<tr>
<td>Topic</td>
<td>Description</td>
</tr>
<tr>
<td>-------</td>
<td>-------------</td>
</tr>
<tr>
<td></td>
<td>may result in financial benefit. Disclosures are obtained prior to the panel member appointments and for 1 year prior to the initiation of their work on the panel. Full transparency of potential financial conflicts is an important goal for the guidance that best ensures the credibility of the process and the recommendations.</td>
</tr>
<tr>
<td></td>
<td>Individuals are also asked to disclose funding of HCV-related research activities to their institutional division, department, or practice group.</td>
</tr>
<tr>
<td></td>
<td>Disclosures are reviewed by the HCV guidance chairs, who make assessments based on the conflict-of-interest policies of the sponsoring organizations (AASLD and IDSA). Personal and institutional financial relationships with commercial entities that have products in the field of hepatitis C are assessed.</td>
</tr>
<tr>
<td></td>
<td>The following relationships are prohibited during membership on the guidance panel and are grounds for exclusion from the panel:</td>
</tr>
<tr>
<td></td>
<td>• Employment with any commercial company with products in the field of hepatitis C</td>
</tr>
<tr>
<td></td>
<td>• An ownership interest in a commercial entity that produces hepatitis C products</td>
</tr>
<tr>
<td></td>
<td>• Participation in/payment for promotional or marketing activities sponsored by companies with HCV-related products including non-CME educational activities or speakers bureaus for audiences outside of the company</td>
</tr>
<tr>
<td></td>
<td>• Participation in any single-funder CME activity</td>
</tr>
<tr>
<td></td>
<td>• Participation on a marketing or medical affairs advisory board</td>
</tr>
<tr>
<td></td>
<td>The following relationships or activities are reportable but do not merit exclusion:</td>
</tr>
<tr>
<td></td>
<td>• Commercial support of research that is paid to an organization or practice group Due to the rapidly evolving nature of the subject matter, having individuals with expertise in the particular clinical topic is crucial to developing the highest-quality and most-informed recommendations. To that end, research support from commercial entities is not considered grounds for panel exclusion (an unresolvable conflict) if the funding of the research was paid to the institution or practice group, as opposed to the individual. In the instance of someone conducting clinical research in a community practice, research funds to the group practice are acceptable.</td>
</tr>
<tr>
<td></td>
<td>• Participation on commercial company scientific advisory boards Participation in advisory boards, data safety monitoring boards, or in consultancies sponsored by the research arm of a company (eg, study design or data safety monitoring board) is considered a potential personal conflict that should be reported but is not considered a criterion for exclusion.</td>
</tr>
<tr>
<td></td>
<td>• CME honorarium earned in excess of $5000 (total per year, including travel costs) No need to report if total honorarium is less than $5000.</td>
</tr>
<tr>
<td></td>
<td>The HCV guidance chairs achieved a majority of panel members with no personal financial interests.</td>
</tr>
<tr>
<td></td>
<td>Panel members are asked to inform the group of any changes to their disclosure status and are given the opportunity to recuse themselves (or be recused) from the discussion where a perceived conflict of interest that cannot be resolved exists.</td>
</tr>
<tr>
<td>Topic</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Financial disclosures for each panel member can be accessed here.</td>
<td></td>
</tr>
<tr>
<td>Intended audience</td>
<td>Medical practitioners, especially those who provide care to or manage patients with hepatitis C, are the intended audience of the guidance.</td>
</tr>
<tr>
<td>Sponsors, funding, and collaborating partner</td>
<td>AASLD and IDSA are the sponsors of the guidance and provide ongoing financial support. Grant support was sought and obtained from CDC for the initial gathering and review of evidence related to hepatitis C screening and testing recommendations and interventions to implement HCV screening in clinical settings.</td>
</tr>
<tr>
<td>Evidence identification and collection</td>
<td>The guidance is developed using an evidence-based review of information that is largely available to healthcare practitioners. Data from the following sources are considered by panel members when making recommendations: research published in the peer-reviewed literature or presented at major national or international scientific conferences; safety warnings from the US Food and Drug Administration (FDA) or other regulatory agencies or from manufacturers; drug interaction data; prescribing information from FDA-approved products; and registration data for new products under FDA review. Press releases, unpublished reports, and personal communications are generally not considered. Literature searches are conducted regularly and before each major revision to ensure that the panel addresses all relevant published data. Medical subject headings and free text terms are combined to maximize retrieval of relevant citations from the PubMed, Scopus, EMBASE, and Web of Science databases. To be considered for inclusion, articles are required to have been published in English from 2010 to the present. Data from abstracts presented at national or international scientific conferences are also considered.</td>
</tr>
<tr>
<td>Rating of the evidence and recommendations</td>
<td>The guidance is presented in the form of recommendations. Each recommendation is rated in terms of the level of the evidence and strength of the recommendation using a modification of the scale adapted from the American College of Cardiology and the American Heart Association Practice Guidelines (AHA, 2011); (Shiffman, 2003). A summary of the supporting (and conflicting) evidence follows each recommendation or set of recommendations.</td>
</tr>
<tr>
<td>Data review and synthesis and preparation of recommendations and supporting information</td>
<td>Draft recommendations are developed by subgroups of the full panel with interest and expertise in particular sections of the guidance. Following development of supporting text and references, the sections are reviewed by the full panel and chairs. A penultimate draft is submitted to the AASLD and IDSA governing boards for final review and approval before posting online on the website, <a href="http://www.hcvguidelines.org">www.hcvguidelines.org</a>. Subgroups of the panel meet regularly by conference call as needed to update recommendations and supporting evidence. Updates may be prompted by new publications or presentations at major national or international scientific conferences, new drug approvals (or new indications, dosing formulations, or frequency of dosing), new safety warnings, or other information that may have a substantial impact on the clinical care of patients. Updates and changes to the guidance are indicated by a notice of update posted on the home page.</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>Commonly used abbreviations in the text are defined in Methods Table 3.</td>
</tr>
</tbody>
</table>
Table 2. Rating System Used to Rate Level of Evidence and Strength of Recommendation

Recommendations are based on scientific evidence and expert opinion. Each recommended statement includes a Roman numeral (I, II, or III) representing the level of the evidence that supports the recommendation and a letter (A, B, or C) representing the strength of the recommendation.

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Evidence and/or general agreement that a given diagnostic evaluation, procedure, or treatment is beneficial, useful, and effective.</td>
</tr>
<tr>
<td>II</td>
<td>Conflicting evidence and/or a divergence of opinion about the usefulness and efficacy of a diagnostic evaluation, procedure, or treatment.</td>
</tr>
<tr>
<td>IIa</td>
<td>Weight of evidence and/or opinion is in favor of usefulness and efficacy.</td>
</tr>
<tr>
<td>IIb</td>
<td>Usefulness and efficacy are less well established by evidence and/or opinion.</td>
</tr>
<tr>
<td>III</td>
<td>Conditions for which there is evidence and/or general agreement that a diagnostic evaluation, procedure, or treatment is not useful and effective or if it in some cases may be harmful.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Data derived from multiple randomized clinical trials, meta-analyses, or equivalent.</td>
</tr>
<tr>
<td>B</td>
<td>Data derived from a single randomized trial, nonrandomized studies, or equivalent.</td>
</tr>
<tr>
<td>C</td>
<td>Consensus opinion of experts, case studies, or standard of care.</td>
</tr>
</tbody>
</table>

Adapted from the American College of Cardiology and the American Heart Association Practice Guidelines (AHA, 2011); (Shiffman, 2003).

In some situations, such as for interferon-sparing HCV treatments, randomized clinical trials with an existing standard-of-care arm cannot ethically or practically be conducted. The US Food and Drug Administration (FDA) has suggested alternative study designs, including historical controls or immediate versus deferred placebo-controlled trials. For additional examples and definitions see FDA link: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf. In those instances for which there was a single predetermined, FDA-approved equivalency established, panel members considered the evidence as equivalent to a randomized controlled trial for levels A or B.

Last update: November 6, 2019
Table 3. Commonly Used Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition and Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACA</td>
<td>Patient Protection and Affordable Care Act</td>
</tr>
<tr>
<td>AFP</td>
<td>alpha-fetoprotein</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>AMP</td>
<td>average manufacturer price</td>
</tr>
<tr>
<td>Anti-HCV</td>
<td>HCV antibody</td>
</tr>
<tr>
<td>APRI</td>
<td>AST-to-platelet ratio index</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the curve</td>
</tr>
<tr>
<td>AWP</td>
<td>average wholesale price&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>BOC</td>
<td>boceprevir</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CEA</td>
<td>cost-effectiveness analysis</td>
</tr>
<tr>
<td>CTP</td>
<td>Child-Turcotte-Pugh (see below)</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DAA</td>
<td>direct-acting antiviral</td>
</tr>
<tr>
<td>eGFR</td>
<td>estimated glomerular filtration rate</td>
</tr>
<tr>
<td>ESRD</td>
<td>end-stage renal disease</td>
</tr>
<tr>
<td>FDA</td>
<td>US Food and Drug Administration</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>HBsAg</td>
<td>hepatitis B virus surface antigen</td>
</tr>
<tr>
<td>HBV</td>
<td>hepatitis B virus</td>
</tr>
<tr>
<td>HCC</td>
<td>hepatocellular carcinoma</td>
</tr>
<tr>
<td>HCV</td>
<td>hepatitis C virus</td>
</tr>
</tbody>
</table>

Hepatitis C virus and HCV refer to the virus. Hepatitis C and HCV infection or HCV
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition and Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>disease refer to the disease entity.</td>
<td></td>
</tr>
<tr>
<td>ICER</td>
<td>incremental cost-effectiveness ratio</td>
</tr>
<tr>
<td>IDU</td>
<td>injection drug use or user</td>
</tr>
<tr>
<td>INR</td>
<td>international normalized ratio</td>
</tr>
<tr>
<td>MELD</td>
<td>model for end-stage liver disease</td>
</tr>
<tr>
<td>MSM</td>
<td>men who have sex with men</td>
</tr>
<tr>
<td>NASH</td>
<td>nonalcoholic steatohepatitis</td>
</tr>
<tr>
<td>NAT</td>
<td>nucleic acid testing</td>
</tr>
<tr>
<td>NIH</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>NS3</td>
<td>HCV nonstructural protein 3</td>
</tr>
<tr>
<td>NS5A</td>
<td>HCV nonstructural protein 5A</td>
</tr>
<tr>
<td>OATP</td>
<td>organic anion-transporting polypeptide</td>
</tr>
<tr>
<td>PBM</td>
<td>pharmacy benefit manager</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>P-gp</td>
<td>P-glycoprotein</td>
</tr>
<tr>
<td>PreP</td>
<td>preexposure prophylaxis</td>
</tr>
<tr>
<td>PWID</td>
<td>people who inject drugs</td>
</tr>
<tr>
<td>QALY</td>
<td>quality-adjusted life-year</td>
</tr>
<tr>
<td>RAS</td>
<td>resistance-associated substitution</td>
</tr>
<tr>
<td>RBC</td>
<td>red blood cell(s)</td>
</tr>
<tr>
<td>RBV</td>
<td>ribavirin</td>
</tr>
<tr>
<td>RGT</td>
<td>response-guided therapy</td>
</tr>
<tr>
<td>sAg</td>
<td>surface antigen</td>
</tr>
<tr>
<td>SMV</td>
<td>simeprevir</td>
</tr>
<tr>
<td>SOF</td>
<td>sofosbuvir</td>
</tr>
<tr>
<td>SVR12 (or 24 or 48, etc)</td>
<td>sustained virologic response at 12 weeks (or at 24 weeks, or at 48 weeks, etc)</td>
</tr>
<tr>
<td>TSH</td>
<td>thyroid-stimulating hormone</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition and Notes</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>TVR</td>
<td>telaprevir</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
<tr>
<td>USPSTF</td>
<td>US Preventive Services Task Force</td>
</tr>
<tr>
<td>WAC</td>
<td>wholesale acquisition cost ( ^b )</td>
</tr>
</tbody>
</table>

\(^a\) "List price" for wholesale pharmacies to purchase drugs
\(^b\) Typically, approximately 17% off of AWP

### Child-Turcotte-Pugh (CTP) Classification of the Severity of Cirrhosis

<table>
<thead>
<tr>
<th>Factor</th>
<th>CLASS A</th>
<th>CLASS B</th>
<th>CLASS C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total bilirubin (µmol/L)</td>
<td>&lt;34</td>
<td>34-50</td>
<td>&gt;50</td>
</tr>
<tr>
<td>Serum albumin (g/L)</td>
<td>&gt;35</td>
<td>28-35</td>
<td>&lt;28</td>
</tr>
<tr>
<td>Prothrombin time / international normalized ratio</td>
<td>&lt;1.7</td>
<td>1.71-2.3</td>
<td>&gt;2.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ascites</th>
<th>None</th>
<th>Mild</th>
<th>Moderate to Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatic encephalopathy</td>
<td>None</td>
<td>Grade I-II (or supressed with medication)</td>
<td>Grade III-IV (or refractory)</td>
</tr>
</tbody>
</table>

**Last update:** November 6, 2019

**Related References**


